ERBB2 and neoplasm: Our newest results support the hypothesis that the anti-tumor action of MSU42011, an RXR agonist, is dependent on a fully functional immune system, present in MMTV-Neu and A/J mice (Figure 2 and Figure 3), but not in athymic nude mice (Figure 6).